sur QUANTEL (EPA:QUA)
Lumibird in Exclusive Talks to Sell Medical Division to IPG Photonics
On July 16, 2026, Lumibird Group announced exclusive negotiations for selling its Medical Division to IPG Photonics Corporation. The deal, valued at €300 million, could increase by €50 million based on performance in 2026 and 2027. This transaction marks a significant milestone, aiming to specialize Lumibird's divisions for future growth.
Historically, Lumibird has invested in innovation and global expansion, establishing strong market positions. The proposed sale would enable Lumibird to concentrate on its Photonics Division, enhancing financial flexibility and strategic clarity, particularly in areas such as Defence & Space and Industrial applications.
IPG Photonics is expected to offer Lumibird's Medical Division extensive industrial capabilities and market reach. The transaction aims to complete by Q4 2026, pending employee consultations and regulatory approvals. Proceeds will strengthen Lumibird's balance sheet, allowing for substantial investment in R&D and potential shareholder distributions.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de QUANTEL